A concerning drug shortage issue with Eli Lilly’s weight loss treatment has led to confusion regarding FDA regulations and compounding pharmacies. The FDA initially declared an end to the shortage, but backtracked after traditional retail pharmacies reported continued unavailability. This marked a rare instance of the FDA changing course on a shortage decision. On another front, AstraZeneca may consider cutting jobs in the UK if the government enforces profit-sharing measures related to genetic codes from nature. The pharmaceutical industry is lobbying against these measures, which aim to address the use of digital sequence information in drug development without proper compensation to biodiverse countries.
Source link
We’re reading about FDA shortages oversight, AstraZeneca threats
